+

WO2007107594A3 - Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors - Google Patents

Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors

Info

Publication number
WO2007107594A3
WO2007107594A3 PCT/EP2007/052712 EP2007052712W WO2007107594A3 WO 2007107594 A3 WO2007107594 A3 WO 2007107594A3 EP 2007052712 W EP2007052712 W EP 2007052712W WO 2007107594 A3 WO2007107594 A3 WO 2007107594A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac
inhibitors
histone deacetylase
membered heterocycle
heterocycle substituted
Prior art date
Application number
PCT/EP2007/052712
Other languages
French (fr)
Other versions
WO2007107594A2 (en
Inventor
Philip Jones
Ontoria Jesus Maria Ontoria
Carsten Schultz-Fademrecht
Original Assignee
Angeletti P Ist Richerche Bio
Philip Jones
Ontoria Jesus Maria Ontoria
Carsten Schultz-Fademrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Philip Jones, Ontoria Jesus Maria Ontoria, Carsten Schultz-Fademrecht filed Critical Angeletti P Ist Richerche Bio
Publication of WO2007107594A2 publication Critical patent/WO2007107594A2/en
Publication of WO2007107594A3 publication Critical patent/WO2007107594A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.
PCT/EP2007/052712 2006-03-21 2007-03-21 Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors WO2007107594A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0605573.5 2006-03-21
GBGB0605573.5A GB0605573D0 (en) 2006-03-21 2006-03-21 Therapeutic Compounds

Publications (2)

Publication Number Publication Date
WO2007107594A2 WO2007107594A2 (en) 2007-09-27
WO2007107594A3 true WO2007107594A3 (en) 2008-09-12

Family

ID=36293110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/052712 WO2007107594A2 (en) 2006-03-21 2007-03-21 Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors

Country Status (2)

Country Link
GB (1) GB0605573D0 (en)
WO (1) WO2007107594A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
JP5422120B2 (en) 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Methods for predicting clinical outcome for epidermal growth factor receptor inhibitors by cancer patients
RU2015124002A (en) 2012-11-20 2017-01-10 Вертекс Фармасьютикалз Инкорпорейтед COMPOUNDS USED AS INDOLAMIN-2,3-DIOXYGENASE INHIBITORS
CN103214413B (en) * 2013-03-22 2015-05-13 郑州泰基鸿诺药物科技有限公司 Trifluoromethyl ketone compound containing heterocycle and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075929A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
WO2003076401A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US20060058553A1 (en) * 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058553A1 (en) * 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase
WO2003075929A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
WO2003076401A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASAMI, K.; ET AL.: "Antimicrobial activity of trifluoromethyl ketones and their synergism with promethazine", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 18, 2001, pages 161 - 165, XP002488062 *

Also Published As

Publication number Publication date
GB0605573D0 (en) 2006-04-26
WO2007107594A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2006061638A3 (en) Heterocycle derivatives as histone deacetylase (hdac) inhibitors
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2007029035A3 (en) Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
WO2007072080A3 (en) Heterocycle substituted ketone derivatives as histone deacetylase (hdac) inhibitors
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2007092095A3 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
WO2010046445A3 (en) Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2008060621A3 (en) Aminopyrrolidines as chemokine receptor antagonists
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2010043953A3 (en) Novel bridged cyclic compounds as histone deacetylase inhibitors
WO2009011850A3 (en) Novel therapeutic compounds
WO2010144499A3 (en) Urea derivatives as kinase inhibitors
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
PH12015501640A1 (en) Azole benzene derivative
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
WO2009082526A3 (en) Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
MX2010002900A (en) Tricyclic heterocyclic derivatives.
WO2007052073A3 (en) Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
WO2007107594A3 (en) Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07727188

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07727188

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载